Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
2.
Sci Adv ; 10(10): eadj6380, 2024 Mar 08.
Artigo em Inglês | MEDLINE | ID: mdl-38446889

RESUMO

Nanomaterials offer unique opportunities to engineer immunomodulatory activity. In this work, we report the Toll-like receptor agonist activity of a nanoscale adjuvant zeolitic imidazolate framework-8 (ZIF-8). The accumulation of ZIF-8 in endosomes and the pH-responsive release of its subunits enable selective engagement with endosomal Toll-like receptors, minimizing the risk of off-target activation. The intrinsic adjuvant properties of ZIF-8, along with the efficient delivery and biomimetic presentation of a severe acute respiratory syndrome coronavirus 2 spike protein receptor-binding domain trimer, primed rapid humoral and cell-mediated immunity in a dose-sparing manner. Our study offers insights for next-generation adjuvants that can potentially impact future vaccine development.


Assuntos
COVID-19 , Zeolitas , Humanos , SARS-CoV-2 , Glicoproteína da Espícula de Coronavírus , Adjuvantes Imunológicos , Endossomos , Receptores Toll-Like , Zeolitas/farmacologia
3.
bioRxiv ; 2023 Apr 16.
Artigo em Inglês | MEDLINE | ID: mdl-37090507

RESUMO

Cancer therapy research is of high interest because of the persistence and mortality of the disease and the side effects of traditional therapeutic methods, while often multimodal treatments are necessary based on the patient's needs. The development of less invasive modalities for recurring treatment cycles is thus of critical significance. Herein, a light-activatable microparticle system was developed for localized, pulsatile delivery of anticancer drugs with simultaneous thermal ablation, by applying controlled ON-OFF thermal cycles using near-infrared laser irradiation. The system is composed of poly(caprolactone) microparticles of 200 µm size with incorporated molybdenum disulfide (MoS 2 ) nanosheets as the photothermal agent and hydrophilic doxorubicin or hydrophobic violacein, as model drugs. Upon irradiation the nanosheets heat up to ≥50 °C leading to polymer matrix melting and release of the drug. MoS 2 nanosheets exhibit high photothermal conversion efficiency and allow for application of low power laser irradiation for the system activation. A Machine Learning algorithm was applied to acquire optimal laser operation conditions; 0.4 W/cm 2 laser power at 808 nm, 3-cycle irradiation, for 3 cumulative minutes. In a mouse subcutaneous model of 4T1 triple-negative breast cancer, 25 microparticles were intratumorally administered and after 3-cycle laser treatment the system conferred synergistic phototherapeutic and chemotherapeutic effect. Our on-demand, pulsatile synergistic treatment resulted in increased median survival up to 40 days post start of treatment compared to untreated mice, with complete eradication of the tumors at the primary site. Such a system could have potential for patients in need of recurring cycles of treatment on subcutaneous tumors.

5.
Cancer Res ; 78(21): 6171-6182, 2018 11 01.
Artigo em Inglês | MEDLINE | ID: mdl-30154145

RESUMO

Breast cancer brain metastases are a deadly sequela of primary breast tumors that overexpress human epidermal growth factor receptor 2 (HER2); median survival for patients with these tumors is 10 to 13 months from the time of diagnosis. Current treatments for HER2-positive breast cancer brain metastases are invasive, toxic, and largely ineffective. Here, we have developed an adeno-associated virus serotype 9 (AAV9) vector to express the anti-HER2 monoclonal antibody trastuzumab (Herceptin) in vivo A single prophylactic intrathecal administration of AAV9.trastuzumab vector in a novel orthotopic Rag1-/- murine xenograft model of HER2-positive breast cancer brain metastases significantly increased median survival, attenuated brain tumor growth, and preserved both the HER2 antigen specificity and the natural killer cell-associated mechanism of action of trastuzumab. When administered as a tumor treatment, AAV9.trastuzumab increased median survival. Dose-escalation studies revealed that higher doses of AAV9.trastuzumab resulted in smaller tumor volumes. Our results indicate that intrathecal AAV9.trastuzumab may provide significant antitumor activity in patients with HER2-positive breast cancer brain metastases.Significance: Intrathecal delivery of trastuzumab via adeno-associated virus has the potential to become a novel, integral part of adjuvant therapy for patients with HER2-positive breast cancer brain metastases. Cancer Res; 78(21); 6171-82. ©2018 AACR.


Assuntos
Neoplasias Encefálicas/terapia , Neoplasias da Mama/terapia , Injeções Espinhais/métodos , Neoplasias/metabolismo , Receptor ErbB-2/metabolismo , Trastuzumab/administração & dosagem , Animais , Neoplasias Encefálicas/secundário , Neoplasias da Mama/patologia , Dependovirus/metabolismo , Sistemas de Liberação de Medicamentos , Feminino , Vetores Genéticos , Proteínas de Homeodomínio/genética , Humanos , Macaca , Macrófagos/metabolismo , Camundongos , Camundongos Endogâmicos NOD , Metástase Neoplásica , Ensaios Antitumorais Modelo de Xenoenxerto
6.
J Eng Edu ; 107(4): 583-610, 2018 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-37786450

RESUMO

Background: Researchers over the last three decades have documented processes of gender and racial/ethnic inequality in engineering education, but little is known about other axes of difference, including the experiences of lesbian, gay, bisexual, transgender, and queer (LGBTQ) persons in engineering. Despite growing interest in LGBTQ inequality generally, prior research has yet to systematically document day-to-day experiences of inequality in engineering along LGBTQ status. Purpose/Hypothesis: In this paper, we utilize survey data of students from eight schools to sketch the landscape of LGBTQ inequality in engineering education. Specifically, we ask, do LGBTQ students experience greater marginalization than their classmates, is their engineering work more likely to be devalued, and do they experience more negative health and wellness outcomes? We hypothesize that LGBTQ students experience greater marginalization and devaluation and worse health and wellness outcomes compared to their non-LGBTQ peers. Data/Method: We analyze novel survey data from 1729 undergraduate students (141 of whom identify as LGBTQ) enrolled in eight U.S. engineering programs. Results: We find that LGBTQ students face greater marginalization, devaluation, and health and wellness issues relative to their peers, and that these health and wellness inequalities are explained in part by LGBTQ students' experiences of marginalization and devaluation in their engineering programs. Further, there is little variation in the climate for LGBTQ students across the eight schools, suggesting that anti-LGBTQ bias may be widespread in engineering education. Conclusions: We call for reflexive research on LGBTQ inequality engineering education and the institutional and cultural shifts therein needed to mitigate these processes and better support LGBTQ students.

7.
Case Rep Med ; 2012: 914035, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-23093975

RESUMO

Posterior reversible encephalopathy syndrome (PRES) is a clinicoradiological syndrome that is characterized by clinical features including headache, altered mental status, cortical blindness, seizures, and other focal neurological signs as well as subcortical edema without infarction on neuroimaging. Under the umbrella of hypertensive encephalopathy, PRES is defined by reversible cerebral edema due to dysfunction of the cerebrovascular blood-brain barrier unit. The pathophysiology of PRES is thought to result from abnormalities in the transmembrane flow of intravascular fluid and proteins caused by two phenomena: one, cerebral autoregulatory failure and two, loss of integrity of the blood-brain barrier. PRES is not a common disease in patients with human immunodeficiency virus (HIV) and AIDS with only three previously reported cases. Both the HIV and end-stage renal disease appear to further compromise the blood brain barrier. Although uncommon, PRES recurrence has been described. To the best of our knowledge, this is the first report demonstrating recurrent PRES in a HIV patient on hemodialysis for end-stage renal disease.

8.
J Clin Invest ; 121(1): 288-95, 2011 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-21135507

RESUMO

Characterizing the TCRα and TCRß chains expressed by T cells responding to a given pathogen or underlying autoimmunity helps in the development of vaccines and immunotherapies, respectively. However, our understanding of complementary TCRα and TCRß chain utilization is very limited for pathogen- and autoantigen-induced immunity. To address this problem, we have developed a multiplex nested RT-PCR method for the simultaneous amplification of transcripts encoding the TCRα and TCRß chains from single cells. This multiplex method circumvented the lack of antibodies specific for variable regions of mouse TCRα chains and the need for prior knowledge of variable region usage in the TCRß chain, resulting in a comprehensive, unbiased TCR repertoire analysis with paired coexpression of TCRα and TCRß chains with single-cell resolution. Using CD8+ CTLs specific for an influenza epitope recovered directly from the pneumonic lungs of mice, this technique determined that 25% of such effectors expressed a dominant, nonproductively rearranged Tcra transcript. T cells with these out-of-frame Tcra mRNAs also expressed an alternate, in-frame Tcra, whereas approximately 10% of T cells had 2 productive Tcra transcripts. The proportion of cells with biallelic transcription increased over the course of a response, a finding that has implications for immune memory and autoimmunity. This technique may have broad applications in mouse models of human disease.


Assuntos
Receptores de Antígenos de Linfócitos T alfa-beta/genética , Receptores de Antígenos de Linfócitos T alfa-beta/metabolismo , Reação em Cadeia da Polimerase Via Transcriptase Reversa/métodos , Alelos , Sequência de Aminoácidos , Animais , Antígenos Virais/imunologia , Regiões Determinantes de Complementaridade , Epitopos/imunologia , Feminino , Humanos , Camundongos , Camundongos Endogâmicos C57BL , Camundongos Knockout , Dados de Sequência Molecular , Orthomyxoviridae/imunologia , RNA Mensageiro/genética , RNA Mensageiro/metabolismo , Linfócitos T Citotóxicos/imunologia , Transcrição Gênica
9.
J Clin Invest ; 120(6): 1885-94, 2010 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-20440073

RESUMO

CD8+ T cell responses to viral infection are characterized by the emergence of dominant and subdominant CTL populations. The immunodominance hierarchies of these populations are highly reproducible for any given spectrum of virus-induced peptide-MHCI complexes and are likely determined by multiple factors. Recent studies demonstrate a direct correlation between naive epitope-specific CD8+ T cell precursor (CTLp) frequency and the magnitude of the response after antigen challenge. Thus, the number of available precursors in the naive pool has emerged as a key predictor of immunodominance. In contrast to this, we report here no consistent relationship between CTLp frequency and the subsequent magnitude of the immune response for 4 influenza virus-derived epitopes following intranasal infection of mice with influenza A virus. Rather, the characteristic, antigen-driven T cell immunodominance hierarchy was determined by the extent of recruitment from the available pool of epitope-specific precursors and the duration of their continued expansion over the course of the infection. These findings suggest possibilities for enhancing protective immune memory by maximizing both the size and diversity of typically subdominant T cell responses through rational vaccine design.


Assuntos
Epitopos de Linfócito T/imunologia , Linfócitos T Citotóxicos/imunologia , Linfócitos T/imunologia , Animais , Antígenos/imunologia , Epitopos/imunologia , Feminino , Vírus da Influenza A/imunologia , Camundongos , Camundongos Endogâmicos , Orthomyxoviridae/imunologia , Peptídeos/imunologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA